U.S. Markets closed
  • S&P Futures

    4,586.50
    +20.25 (+0.44%)
     
  • Dow Futures

    34,529.00
    +72.00 (+0.21%)
     
  • Nasdaq Futures

    16,239.00
    +88.50 (+0.55%)
     
  • Russell 2000 Futures

    2,216.50
    +19.20 (+0.87%)
     
  • Gold

    1,772.30
    -1.30 (-0.07%)
     
  • Silver

    22.61
    -0.15 (-0.68%)
     
  • EUR/USD

    1.1331
    -0.0008 (-0.0680%)
     
  • 10-Yr Bond

    1.4430
    -0.1610 (-10.04%)
     
  • Vix

    27.19
    +10.08 (+58.91%)
     
  • GBP/USD

    1.3300
    -0.0001 (-0.0080%)
     
  • USD/JPY

    113.4050
    +0.2250 (+0.1988%)
     
  • BTC-USD

    57,023.18
    -283.06 (-0.49%)
     
  • CMC Crypto 200

    1,463.81
    -4.12 (-0.28%)
     
  • FTSE 100

    7,059.45
    -231.75 (-3.18%)
     
  • Nikkei 225

    27,914.37
    +92.61 (+0.33%)
     

What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report

·3 min read
What Investors Should Pay Attention to in AbbVie's Q3 Earnings Report
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

With AbbVie's (NYSE: ABBV) third-quarter earnings report scheduled for Oct. 29, shareholders and prospective investors should be on alert. AbbVie is in the middle of transitioning its revenue base away from dependence on its blockbuster drug Humira, as its exclusivity protections are starting to expire outside the U.S. That means the company's stock is in a particularly sensitive time, as the prospective replacements for Humira are still in the process of ramping up. The earnings report will likely give investors updates on progress in the clinical trial pipeline, but the main dish will be the story about the pace of its revenue growth in Humira's replacements, or lack thereof.